Company logo

SRNE - Sorrento Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Diego, United States

SRNE price evolution
SRNE
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Current assets
Cash $111.91 $36.66 $39.73 $77.29
Short term investments $158.75 $90.22 $122.93 $34.41
Net receivables $24.67 $18.71 $16.45 $22.44
Inventory $14.09 $8.11 $5.43 $2.68
Total current assets $331.12 $172.99 $200.72 $155.26
Long term investments $50.67 $51.27 $51.12 $162.96
Property, plant & equipment $126.6 $126.5 $122.42 $83.76
Goodwill & intangible assets $338.2 $339.23 $373.86 $374.9
Total noncurrent assets $524.52 $521.83 $552.07 $623.66
Total investments $209.42 $141.49 $174.05 $197.37
Total assets $855.64 $694.82 $752.79 $778.92
Current liabilities
Accounts payable $25.02 $27.41 $27.84 $33.97
Deferred revenue $118.34 $120.05 $121.49 $121.85
Short long term debt $69.39 $43.52 $39.13 $33.78
Total current liabilities $204.23 $139.45 $175.18 $180.45
Long term debt $179.49 $194.06 $163.43 $130.96
Total noncurrent liabilities $425.21 $477.24 $446.28 $412.94
Total debt $248.88 $237.58 $202.56 $164.74
Total liabilities $629.44 $616.69 $621.46 $593.39
Shareholders' equity
Retained earnings -$1427.42 -$1386.6 -$1242.19 -$1122.38
Other shareholder equity -$0.22 $1.03 $1.16 $1.13
Total shareholder equity $226.54 $78.75 $131.5 $186.17
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $36.66 $56.46 $80.77 $213.33
Short term investments $90.22 $0.3
Net receivables $18.71 $15.51 $14.45 $3.83
Inventory $8.11 $1.83 $3.36 $2.9
Total current assets $172.99 $86.23 $67.59 $179.56
Long term investments $51.27 $256.4 $262.24 $264.99
Property, plant & equipment $126.5 $73.91 $76.27 $24.38
Goodwill & intangible assets $339.23 $117.23 $101.61 $104.58
Total noncurrent assets $521.83 $449.59 $490.04 $444.52
Total investments $141.49 $256.4 $262.24 $265.29
Total assets $694.82 $535.82 $557.63 $624.09
Current liabilities
Accounts payable $27.41 $25.1 $28.54 $25.13
Deferred revenue $120.05 $117.67 $118.03 $118.98
Short long term debt $43.52 $26.83 $39.58 $10.15
Total current liabilities $139.45 $96.48 $115.21 $61.62
Long term debt $194.06 $142.56 $251.2 $223.14
Total noncurrent liabilities $477.24 $298.61 $409.67 $354.97
Total debt $237.58 $169.39 $290.78 $233.29
Total liabilities $616.69 $395.09 $524.88 $416.59
Shareholders' equity
Retained earnings -$1386.6 -$958.28 -$659.82 -$367.75
Other shareholder equity $1.03 $0.52 -$0.27 $0.01
Total shareholder equity $78.75 $165.15 $78.59 $209.47
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Revenue
Total revenue $18.39 $13.08 $12.06 $13.51
Cost of revenue $5.76 $3.14 $3.39 $3.12
Gross Profit $12.63 $9.94 $8.68 $10.39
Operating activities
Research & development $63.98 $59.13 $49.45 $54.51
Selling, general & administrative $44.33 $54.58 $48.49 $50.39
Total operating expenses $121.61 $124.55 $110.06 $110.94
Operating income -$108.98 -$114.61 -$101.39 -$100.55
Income from continuing operations
EBIT -$36.1 -$174.53 -$116.52 -$165.24
Income tax expense $1.46 -$33.05 $0.39 -$0.64
Interest expense $3.25 $2.94 $2.9 $2.02
Net income
Net income -$40.81 -$144.42 -$119.8 -$166.62
Income (for common shares) -$40.81 -$144.42 -$119.8 -$166.62
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $52.9 $39.99 $31.43 $21.19
Cost of revenue $13.03 $9.94 $12.24 $7.06
Gross Profit $39.87 $30.05 $19.2 $14.13
Operating activities
Research & development $206.92 $111.34 $106.88 $76.96
Selling, general & administrative $196.86 $116.18 $103.56 $63.64
Total operating expenses $441.32 $274.56 $278.59 $164.56
Operating income -$401.45 -$244.52 -$259.39 -$150.43
Income from continuing operations
EBIT -$451.62 -$280.29 -$256.4 -$152.18
Income tax expense -$33.52 -$2.01 -$0.47 -$6.27
Interest expense $10.22 $20.18 $36.14 $57.63
Net income
Net income -$428.32 -$298.46 -$292.07 -$203.54
Income (for common shares) -$428.32 -$298.46 -$292.07 -$203.54
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Net income -$40.81 -$144.42 -$119.8 -$166.62
Operating activities
Depreciation $4.29 $3.66 $5.11 $3.87
Business acquisitions & disposals -$11.07 -$0.65 -$22.37 -$13.02
Stock-based compensation $20.79 $22.68 $21.1 $22.75
Total cash flows from operations -$83.36 -$72.14 -$83.11 -$78.52
Investing activities
Capital expenditures -$2.59 -$2.21 -$1.18 -$3.49
Investments $0.65 $28.94 $95.17
Total cash flows from investing -$13.66 -$2.21 $5.4 $78.66
Financing activities
Dividends paid
Sale and purchase of stock $164.56 $69.11 $43.2 $50.75
Net borrowings $8.8 $1.75 -$3.14 -$17.07
Total cash flows from financing $173.37 $70.86 $40.06 $35.06
Effect of exchange rate -$1.1 $0.41 $0.1 $0.41
Change in cash and equivalents $76.34 -$3.48 -$37.66 $35.2
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$428.32 -$298.46 -$292.07 -$203.54
Operating activities
Depreciation $16.32 $14.71 $15.04 $9.05
Business acquisitions & disposals -$36.05 -$2.34 -$26.73 -$10
Stock-based compensation $90.19 $31.42 $12.65 $6.21
Total cash flows from operations -$281.82 -$159.54 -$173 -$111.77
Investing activities
Capital expenditures -$8.87 -$6.53 -$11.44 -$11.2
Investments $124.77
Total cash flows from investing $79.85 -$39.92 -$38.17 -$21.2
Financing activities
Dividends paid
Sale and purchase of stock $217.25 $416.22 $47.7 $83.82
Net borrowings -$35.91 -$186.98 $22.34 $273.38
Total cash flows from financing $181.33 $174.24 $78.89 $326
Effect of exchange rate $0.84 $0.92 -$0.28 -$0.14
Change in cash and equivalents -$20.64 -$25.22 -$132.28 $193.04
Fundamentals
Market cap $790.34M
Enterprise value $927.32M
Shares outstanding 367.60M
Revenue $57.03M
EBITDA -$475.46M
EBIT -$492.39M
Net Income -$471.65M
Revenue Q/Q 28.97%
Revenue Y/Y 22.60%
P/E ratio -1.68
EV/Sales 16.26
EV/EBITDA -1.95
EV/EBIT -1.88
P/S ratio 13.86
P/B ratio 3.49
Book/Share 0.62
Cash/Share 0.30
EPS -$1.28
ROA -61.21%
ROE -302.84%
Debt/Equity 7.83
Net debt/EBITDA -1.09
Current ratio 1.62
Quick ratio 1.55